Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Amy Feller who wrote (755)	11/26/1998 12:37:00 AM
From: Bajasurfer	Read Replies (1) \| Respond to of 1754

PICKED THIS UP FROM THE YAHOO BOARD. 10 x Sales? by: bajasurfer I would like to respond to your post. Let me give you some historical data on VISX sales trends: 1997 1998 Qtr 1 15,743 24,310 Qtr 2 15,595 31,663 Qtr 3 17,967 35,844 Actual P/E on Visx at year end is projected at 25. The real beauty of VISX is in the profitability. They have no debt and are an absolute cash cow. But there is another huge key to VISX! In recent days VISX stock has been picked up not by us little guys... but has gone into strong institutional ownership (something is up big time at VISX). The institutional ownership now stands at a unbelievable 90% (88.56 to be exact). WOULD INSTITUTIONS BE BUYING HEAVILY FOR A MINIMAL GAIN? VISX has 8.8 million shares in the float. That leaves a whopping one million shares in the actual float! There currently are over 1.1 million shares short as of November, check it out yourself (http://www.viwes.com/invest/shorts). I really believe this all adds up to a possible rally of a lifetime! A high stock price by Christmas is possibile. (80's to 100). I would then expect VISX to split the stock! Concerning the long term, I believe the stock price is way too cheap. You may not know as much as you think you do! Visx is investing heavily in R&D and has proven itself the clear winner in technology issues. I personally expect a early settlement with the FTC concerning the allegations. What you are more likely to see is a continued consolidation in this industry (beam/autonomous) as an example. LASE is a real takeover candidate for VISX. There also remains huge barriers to bringing technology to the marketplace. Just ask Nidek and B&L from our friendly FDA. The opinion I saw from Ophthalmologists at the AAO was that they had no intention of switching from VISX at all. They want the largest portfolio of product delivered to their patients (nearsightedness, farsightedness and astigmatism). They were VERY UNWILLING TO CONSIDER SWITCHING unless there were all three procedures being offered by a competitors laser. VISX is built to turn a profit today and well into the next century. Competitors like Summit and B&L have proven unable to do this. Nidek may (because of management) be able to offer more competition to VISX. But I believe VISX will remain the leader for many, many years to come. Thank you VISX for a Great Thanksgiving. Baja